Enliven Therapeutics (ELVN) 10-Q 25 Oct 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Oct. 20, 2022
Cover [Abstract]
Entity Registrant Name	IMARA INC.
Document Type	10-Q
Trading Symbol	IMRA
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		26,287,264
Amendment Flag	false
Entity Central Index Key	0001672619
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Title of 12(b) Security	Common stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity File Number	001-39247
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-1523849
Entity Address, Address Line One	116 Huntington Avenue
Entity Address, Address Line Two	6th Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02116
City Area Code	617
Local Phone Number	206-2020
Document Quarterly Report	true
Document Transition Report	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 49,491	$ 48,309
Short-term investments	6,813	41,969
Prepaid expenses and other current assets	2,800	2,418
Total current assets	59,104	92,696
Property and equipment, net		250
Right of use assets - operating leases		525
Other assets		175
Total assets	59,104	93,646
Current liabilities:
Accounts payable	767	2,360
Accrued expenses and other current liabilities	1,051	4,604
Operating lease liability, current		246
Total current liabilities	1,818	7,210
Operating lease liability, non-current		406
Total liabilities	1,818	7,616
Commitments and contingencies (Note 7)
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued or outstanding as of September 30, 2022; no shares authorized, issued or outstanding as of December 31, 2021
Common stock, $0.001 par value per share; 200,000,000 shares authorized as of September 30, 2022 and December 31, 2021, respectively; 26,287,264 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	27	27
Additional paid-in capital	235,457	233,516
Accumulated other comprehensive income	(4)	(16)
Accumulated deficit	(178,194)	(147,497)
Total stockholders’ equity	57,286	86,030
Total liabilities and stockholders’ equity	$ 59,104	$ 93,646

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	26,287,264	26,287,264
Common stock, shares outstanding	26,287,264	26,287,264

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 182	$ 10,397	$ 18,760	$ 27,586
General and administrative	4,649	3,262	12,253	9,522
Total operating expenses	4,831	13,659	31,013	37,108
Loss from operations	(4,831)	(13,659)	(31,013)	(37,108)
Total other income, net:
Interest income	242	30	430	161
Other expense	(20)	(18)	(114)	(118)
Total other income, net	222	12	316	43
Net loss	(4,609)	(13,647)	(30,697)	(37,065)
Net loss attributable to common stockholders—basic and diluted	$ (4,609)	$ (13,647)	$ (30,697)	$ (37,065)
Weighted-average common shares outstanding—basic	26,287,264	24,898,346	26,287,264	20,099,976
Weighted-average common shares outstanding—diluted	26,287,264	17,715,474	26,287,264	17,647,476
Net loss per share attributable to common stockholders—basic	$ (0.18)	$ (0.55)	$ (1.17)	$ (1.84)
Net loss per share attributable to common stockholders—diluted	$ (0.44)	$ (0.74)	$ (0.99)	$ (1.33)
Comprehensive loss:
Net loss	$ (4,609)	$ (13,647)	$ (30,697)	$ (37,065)
Other comprehensive income:
Unrealized gain (loss) on investments	31	(2)	12	(6)
Comprehensive loss	$ (4,578)	$ (13,649)	$ (30,685)	$ (37,071)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	July 2021 Offering	COMMON STOCK	COMMON STOCK July 2021 Offering	ADDITIONAL PAID-IN CAPITAL	ADDITIONAL PAID-IN CAPITAL July 2021 Offering	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	ACCUMULATED DEFICIT
Beginning balance at Dec. 31, 2020	$ 84,435		$ 18		$ 180,526		$ 4	$ (96,113)
Beginning balance, shares at Dec. 31, 2020			17,548,263
Stock-based compensation expense	947				947
Exercise of stock options	472				472
Exercise of stock options, shares			68,279
Unrealized gain (loss) on investments	(3)						(3)
Net loss	(10,257)							(10,257)
Ending balance at Mar. 31, 2021	75,594		$ 18		181,945		1	(106,370)
Ending balance, shares at Mar. 31, 2021			17,616,542
Beginning balance at Dec. 31, 2020	84,435		$ 18		180,526		4	(96,113)
Beginning balance, shares at Dec. 31, 2020			17,548,263
Net loss	(37,065)
Ending balance at Sep. 30, 2021	99,373		$ 27		232,526		(2)	(133,178)
Ending balance, shares at Sep. 30, 2021			26,275,722
Beginning balance at Mar. 31, 2021	75,594		$ 18		181,945		1	(106,370)
Beginning balance, shares at Mar. 31, 2021			17,616,542
Stock-based compensation expense	917				917
Issuance of common stock under ATM offering, net of issuance costs	1,345		$ 1		1,344
Issuance of common stock under ATM offering, net of issuance costs, shares			231,291
Exercise of stock options and issuance of stock under the Employee Stock Purchase Plan	273				273
Exercise of stock options and issuance of stock under the Employee Stock Purchase Plan, shares			63,104
Unrealized gain (loss) on investments	(1)						(1)
Net loss	(13,161)							(13,161)
Ending balance at Jun. 30, 2021	64,967		$ 19		184,479			(119,531)
Ending balance, shares at Jun. 30, 2021			17,910,937
Stock-based compensation expense	1,003				1,003
Issuance of common stock under ATM offering, net of issuance costs		$ 46,907		$ 8		$ 46,899
Issuance of common stock under ATM offering, net of issuance costs, shares				8,333,333
Exercise of stock options and issuance of stock under the Employee Stock Purchase Plan	145				145
Exercise of stock options and issuance of stock under the Employee Stock Purchase Plan, shares			31,452
Unrealized gain (loss) on investments	(2)						(2)
Net loss	(13,647)							(13,647)
Ending balance at Sep. 30, 2021	99,373		$ 27		232,526		(2)	(133,178)
Ending balance, shares at Sep. 30, 2021			26,275,722
Beginning balance at Dec. 31, 2021	86,030		$ 27		233,516		(16)	(147,497)
Beginning balance, shares at Dec. 31, 2021			26,287,264
Stock-based compensation expense	1,056				1,056
Unrealized gain (loss) on investments	(35)						(35)
Net loss	(14,639)							(14,639)
Ending balance at Mar. 31, 2022	72,412		$ 27		234,572		(51)	(162,136)
Ending balance, shares at Mar. 31, 2022			26,287,264
Beginning balance at Dec. 31, 2021	86,030		$ 27		233,516		(16)	(147,497)
Beginning balance, shares at Dec. 31, 2021			26,287,264
Net loss	(30,697)
Ending balance at Sep. 30, 2022	57,286		$ 27		235,457		(4)	(178,194)
Ending balance, shares at Sep. 30, 2022			26,287,264
Beginning balance at Mar. 31, 2022	72,412		$ 27		234,572		(51)	(162,136)
Beginning balance, shares at Mar. 31, 2022			26,287,264
Stock-based compensation expense	385				385
Unrealized gain (loss) on investments	16						16
Net loss	(11,449)							(11,449)
Ending balance at Jun. 30, 2022	61,364		$ 27		234,957		(35)	(173,585)
Ending balance, shares at Jun. 30, 2022			26,287,264
Stock-based compensation expense	500				500
Unrealized gain (loss) on investments	31						31
Net loss	(4,609)							(4,609)
Ending balance at Sep. 30, 2022	$ 57,286		$ 27		$ 235,457		$ (4)	$ (178,194)
Ending balance, shares at Sep. 30, 2022			26,287,264

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2021	Jun. 30, 2021
Stock issuance costs		$ 357
July 2021 Offering
Stock issuance costs	$ 210

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (30,697)	$ (37,065)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,941	2,867
Depreciation expense	612	74
Amortization and accretion on investments	110	103
Non-cash lease expense	(12)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(382)	(975)
Accounts payable	(1,593)	505
Accrued expenses and other current liabilities	(3,553)	229
Operating lease assets and liabilities, net	(114)	(24)
Net cash used in operating activities	(33,688)	(34,286)
Cash flows from investing activities:
Proceeds from maturities and sales of short-term investments	35,058	42,637
Purchases of short-term investments		(29,766)
Purchases of property and equipment	(363)	(12)
Net cash provided by investing activities	34,695	12,859
Cash flows from financing activities:
Proceeds from July 2021 offering, net of underwriting discounts and commissions		47,000
Proceeds from ATM offering, net of underwriting discounts and commissions		1,818
Payment of issuance costs		(567)
Proceeds from exercise of options		860
Net cash provided by financing activities		49,111
Net increase in cash, cash equivalents and restricted cash	1,007	27,684
Cash, cash equivalents and restricted cash, beginning of period	48,484	47,786
Cash, cash equivalents and restricted cash, end of period	49,491	75,470
Supplemental disclosure of non-cash investing and financing activities:
Right of use asset obtained in exchange for lease liabilities	1,886
Unrealized loss on investments	$ 12	$ (6)

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical) $ in Thousands	Sep. 30, 2021 USD ($)
Statement Of Cash Flows [Abstract]
Cash and cash equivalents	$ 75,295
Restricted cash (included in other assets)	175
Total cash, cash equivalents and restricted cash	$ 75,470

Nature of the Business

Nature of the Business	9 Months Ended
	Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of the Business	1. Nature of the Business IMARA Inc. (“IMARA” or the “Company”) is a biopharmaceutical company that has been dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious diseases. The Company was incorporated in January 2016 under the laws of the State of Delaware, and its principal offices are in Boston, Massachusetts. On April 5, 2022, the Company announced the results from interim analyses of its Ardent Phase 2b clinical trial of tovinontrine (IMR-687) in patients with sickle cell disease (“SCD”) and Forte Phase 2b clinical trial of tovinontrine in patients with ß-thalassemia. Based on the data generated by these interim analyses, the Company decided to discontinue the Ardent and Forte trials as well as the further development of tovinontrine in SCD and ß-thalassemia. The Company also decided to discontinue development of tovinontrine in heart failure with preserved ejection fraction, as well as its development plans with respect to IMR-261. In connection with these events, the Company’s Board of Directors approved a reduction in workforce designed to substantially reduce the Company’s operating expenses while it undertakes a comprehensive assessment of its strategic options to maximize stockholder value. The Workforce Reduction was completed as of September 30, 2022 and the Company incurred approximately $2.1 million of expenses comprised of notice and employee severance and retention payments. On September 6, 2022, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Cardurion Pharmaceuticals, Inc. (“Cardurion”), discussed further in Note 14, providing for the sale of tovinontrine and all other assets of the Company related to its PDE9 program (the “Asset Sale”). On October 13, 2022, the Company, Iguana Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), and Enliven Therapeutics, Inc., a Delaware corporation (“Enliven”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), discussed further in Note 15, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Enliven, with Enliven continuing as a wholly owned subsidiary of IMARA and the surviving corporation of the merger (the “Merger”). If the Merger is completed, the business of Enliven will continue as the business of the combined organization. The closing of the transactions contemplated by the Asset Purchase Agreement between IMARA and Cardurion is a condition to the closing of the transactions contemplated by the Merger Agreement. Consummation of the Asset Sale and Merger Agreement is subject to customary closing conditions, including, without limitation, approval of the sale by the Company’s stockholders. Liquidity The Company has incurred recurring negative cash flows since inception and has funded its operations primarily from the sale of convertible preferred stock and proceeds from the IPO and subsequent common stock offerings. As of September 30, 2022, the Company had cash, cash equivalents, and investments of $56.3 million and an accumulated deficit of approximately $178.2 million. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future. On April 1, 2021, the Company filed a Registration Statement on Form S-3 (the “Shelf”) with the SEC in relation to the registration and potential future issuance of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $200.0 million. The Shelf was declared effective on April 8, 2021. The Company also simultaneously entered into a sales agreement with Cantor Fitzgerald & Co, LLC, as sales agent, providing for the offering, issuance and sale by the Company of up to an aggregate $75.0 million of its common stock from time to time in “at-the-market” offerings under the Shelf. As of September 30, 2022, the Company had issued and sold 231,291 shares of common stock under the sales agreement, resulting in net proceeds of $1.4 million after deducting commissions and offering expenses. On July 16, 2021, the Company completed a public offering of shares of its common stock. In connection with the offering, the Company issued and sold 8,333,333 shares of common stock at a public offering price of $6.00 per share, resulting in net proceeds of $46.8 million after deducting underwriting discounts and commissions and offering expenses. As described above, the Company made the decision to discontinue development of tovinontrine in sickle cell disease, β-thalassemia and heart failure with preserved ejection fraction, as well to discontinue its development plans with respect to IMR-261. As a result and without giving effect to the Asset Sale, the Company believes its cash, cash equivalents and investments as of September 30, 2022 will be sufficient to fund its operating expense requirements for at least twelve months from the date of filing this Quarterly Report on Form 10-Q. In the event that the Company does not complete the Asset Sale or the Merger, the Company (i) may elect to pursue a dissolution and liquidation of the Company, (ii) pursue another strategic transaction or (iii) may resume research and development activities. If the Company decides to pursue any future product development efforts, it will need additional funding to support its planned operating activities. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021 and notes thereto, included in the Company’s Annual Report on Form 10-K (the “Annual Report”), filed with the SEC on March 15, 2022. The unaudited condensed consolidated interim financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated interim financial statements contain all adjustments which are necessary to present fairly the Company’s financial position as of September 30, 2022, the results of its operations for the three and nine months ended September 30, 2022 and 2021 and cash flows for the nine months ended September 30, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results for the year ending December 31, 2022, or for any future period. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company include the accounts of its wholly owned subsidiaries, IMARA Security Corporation and IMARA E.U. Limited, the latter of which was dissolved in July 2021. All intercompany transactions and balances have been eliminated in consolidation. Summary of Significant Accounting Policies The significant accounting policies and estimates used in the preparation of the accompanying unaudited condensed consolidated financial statements are described in the Company’s audited consolidated financial statements for the year ended December 31, 2021 included in the Company’s Annual Report. There have been no material changes in the Company’s significant accounting policies during the three and nine months ended September 30, 2022. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued research and development expenses, and stock-based compensation expense. Actual results could differ materially from those estimates. Segments Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purpose of allocating resources. All of the Company’s long-lived assets are held in the United States. Comprehensive Loss Comprehensive loss includes net loss and certain changes in stockholders’ equity that are excluded from net loss. The Company’s comprehensive loss includes unrealized gains and losses (net) on available-for-sale debt securities for the three and nine months ended September 30, 2022 and 2021. Recently Issued Accounting Pronouncements In March 2020, the FASB issued “ASU 2020-03”, Codification Improvements to Financial Instruments (“ASU 2020-03”) which addressed, among other topics, Amendments related to ASU 2016-13 Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13”). The amendments align the contractual term under Topic 326 and Topic 842 (Leases) to be consistent, and also clarifies when an entity should record an allowance for credit losses in accordance with Topic 326. The standard is effective for the Company on January 1, 2023, with early adoption permitted. The Company is currently evaluating the impact of this new guidance on the Company’s consolidated financial statements and related disclosures, but does not expect the adoption of ASU 2020-03 or ASU 2016-13 to be material.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities	3. Fair Value of Financial Assets and Liabilities The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands): September 30, 2022 Quoted Active for Assets Significant Observable Inputs Significant Observable Inputs Description Total (Level 1) (Level 2) (Level 3) Assets: Money market funds, included in cash and cash equivalents $ 46,252 $ 46,252 $ — $ — Marketable securities: Commercial paper 4,397 — 4,397 — Corporate debt securities 2,416 — 2,416 — Total financial assets $ 53,065 $ 46,252 $ 6,813 $ — December 31, 2021 Quoted Active for Assets Significant Observable Inputs Significant Observable Inputs Description Total (Level 1) (Level 2) (Level 3) Assets: Money market funds, included in cash and cash equivalents $ 24,798 $ 24,798 $ — $ — Marketable securities: Commercial paper 26,131 — 26,131 — Corporate debt securities 15,838 — 15,838 — Total financial assets $ 66,767 $ 24,798 $ 41,969 $ — As of September 30, 2022 and December 31, 2021, the Company’s Level 1 financial assets consisted of cash equivalents held in money market funds, which are valued using quoted market prices in active markets without any valuation adjustment. The financial assets valued based on Level 2 inputs consist of corporate debt securities and commercial paper, which consist of investments in highly-rated investment-grade securities. The Company estimates the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The Company validates the prices provided by its third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. During the three and nine months ended September 30, 2022 and the year ended December 31, 2021, there were no transfers between fair value measurement levels. The carrying values of other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.

Investments

Investments	9 Months Ended
	Sep. 30, 2022
Investments Debt And Equity Securities [Abstract]
Investments	4. Investments As of September 30, 2022 and December 31, 2021, the Company had short-term investments consisting of corporate debt securities and commercial paper, which are considered to be available-for-sale investments. These are included in short-term investments on the condensed consolidated balance sheets. The following table summarizes the Company’s investments (in thousands): September 30, 2022 Amortized Gross Gains Gross Loss Fair Current: Commercial paper $ 4,397 $ — $ — $ 4,397 Corporate debt securities 2,420 — (4 ) 2,416 Total $ 6,817 $ — $ (4 ) $ 6,813 December 31, 2021 Amortized Gross Gains Gross Loss Fair Current: Commercial paper $ 26,131 $ — $ — $ 26,131 Corporate debt securities 15,854 — (16 ) 15,838 Total $ 41,985 $ — $ (16 ) $ 41,969 As of September 30, 2022, the Company held one available-for-sale securities with an aggregate value of approximately $2.4 million in an unrealized loss position for less than twelve months. As of December 31, 2021, the Company held seven available-for-sale securities in unrealized loss positions with an aggregate value of approximately $15.8 million in an unrealized loss position for less than twelve months. The Company has the intent and ability to hold such securities until recovery. The Company determined that there was no material change in the credit risk of these investments

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2022
Payables And Accruals [Abstract]
Accrued Expenses	5. Accrued Expenses Accrued expenses consisted of the following (in thousands): September 30, 2022 December 31, 2021 Accrued research and development expenses $ 136 $ 2,288 Accrued compensation and benefits 164 2,024 Accrued professional services 733 249 Accrued other 18 43 Total accrued expenses $ 1,051 $ 4,604 Accrued Research and Development Expenses The Company’s accrued research and development expenses related to tovinontrine and IMR-261 significantly declined in the second and third quarters of 2022 following the Company’s April 2022 decision to discontinue development of each program. Restructuring Costs On April 12, 2022, the Company’s Board of Directors approved a reduction of the Company’s workforce (the “Workforce Reduction”) by approximately 83% across all areas of the Company, to a total of six remaining full-time employees. The Workforce Reduction followed the Company’s decision to discontinue development of tovinontrine, as well to discontinue its development plans with respect to IMR-261. The Workforce Reduction was substantially completed during the three and nine months ended September 30, 2022. The Company incurred total expenses relating to the Workforce Reduction of approximately $2.1 million, which was comprised of notice and employee severance and retention payments. The Company recorded these charges in accordance with ASC 420, Exit or Disposal Cost Obligations, and have included them as operating expenses in the condensed statements of operations and comprehensive loss. The Workforce Reduction was completed as of September 30, 2022.

License Agreements

License Agreements	9 Months Ended
	Sep. 30, 2022
License Agreements [Abstract]
License Agreements	6. License Agreements Agreement with Lundbeck In April 2016, the Company entered into a license agreement with Lundbeck A/S (“Lundbeck” and the “Lundbeck Agreement”) pursuant to which Lundbeck granted the Company the following licenses within the field of prevention, treatment or diagnosis of hemoglobinopathy disorders and/or other diseases or disorders, including those directly or indirectly related to hemoglobinopathies: (1) an exclusive, royalty-bearing license to certain patent rights and certain know-how owned or otherwise controlled by Lundbeck (“Licensed Technology”) to research, develop, make, use, sell, and commercialize products (“Licensed Products”) from PDE9 inhibitors, which included tovinontrine (“Licensed Compounds”); (2) a non-exclusive license to the Licensed Technology to make, research, develop, and use such Licensed Technology to enable research and development, with certain restrictions; and (3) a sublicensing right that allows the Company to grant sublicenses to third parties to use the Licensed Technology subject to the certain terms detailed in the Lundbeck Agreement. Under the Lundbeck Agreement, the Company is subject to certain achievement dates for development milestones as defined in the agreement. The regulatory milestones due under the Lundbeck Agreement depend on the products being developed. Development milestones due under the Lundbeck Agreement with respect to the Licensed Compounds total up to $23.5 million, and, for any products that contain PDE9 inhibitors other than Licensed Compounds, total up to $11.8 million. The Company also agreed to pay tiered royalties based on net sales of all products licensed under the agreement in the low single-digit percentages. To date, pursuant to the Lundbeck Agreement, the Company has made cash payments to Lundbeck of $1.8 million consisting of an upfront payment and ongoing milestone payments, which were recorded as research and development expenses. No payments were made during the year ended December 31, 2021, or for the three and nine months ended September 30, 2022. As partial consideration for the license, the Company issued 167,523 shares of common stock to Lundbeck, which represented 8.0% of the Company’s then outstanding equity pursuant to a restricted stock agreement. The shares were fully vested on the date of issuance. The Company also allowed Lundbeck to participate in the fourth tranche of its Series A preferred stock financing in November 2018 at $1.00 per share. The Lundbeck Agreement can be terminated by the Company at any time with 180 days’ written notice. The Company or Lundbeck may terminate the agreement by written notice within a specified period of time in the event of a material breach. In connection with the Asset Sale, the Lundbeck Agreement will be assigned to Cardurion.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Lease Agreements In May 2019, the Company entered into an operating lease agreement (the “May 2019 Lease Agreement”) for office space totaling 4,210 square feet, located in Boston, Massachusetts with a 62-month term. The lease included a rent escalation clause which resulted in cash rental payments of approximately $0.3 million annually. Rent expense was being recognized on a straight-line basis over the lease term. In addition to the base rent, the Company was also responsible for its share of operating expenses, electricity and real estate taxes, in accordance with the terms of the May 2019 Lease Agreement. The Company provided a security deposit of approximately $0.1 million in May 2019, which was included as a component of other assets on the Company’s consolidated balance sheet as of December 31, 2021. The Company occupied the space in August 2019 and commenced recognition of rent expense. In June 2021, the Company entered into an amendment to the May 2019 Lease Agreement (the “June 2021 Amended Lease Agreement”). Under the terms of the June 2021 Amended Lease Agreement, the Company expanded its current premises in Boston, Massachusetts by an additional 5,026 square feet, bringing the total office space to 9,236 square feet. The term of the June 2021 Amended Lease Agreement commenced in February 2022 and, prior to the early termination of the lease discussed below, was set to expire on March 31, 2027. Upon commencement of the term of the June 2021 Amended Lease Agreement, the annual base rent obligation increased to approximately $0.6 million, with a total cash obligation for base rent over the initial five-year term of the lease of approximately $3.1 million. In addition to the base rent, the Company was also responsible for its share of operating expenses, electricity and real estate taxes. Upon execution of the June 2021 Amended Lease Agreement, the Company provided an additional security deposit in the amount of $0.1 million, with security deposits under the May 2019 Lease Agreement and June 2021 Amended Lease Agreement totaling $0.2 million. In July 2022, the Company entered into a second amendment and termination of office lease agreement (the “Termination Agreement”) to terminate the lease under the May 2019 Lease Agreement, as amended by the June 2021 Amended Lease Agreement. The termination of the lease became effective on August 7, 2022 as a result of the landlord entering into a new lease agreement with a third-party tenant for the premises covered by the lease. As part of the Termination Agreement the Company paid a lease termination fee of $0.3 million, which was comprised of forfeiture of its $0.2 million security deposit and an additional fee of $0.1 million. In connection with this termination the Company remeasured its right of use assets and operating lease liabilities and recorded a gain of less than $ 0.1 million. T he Company revised the estimated useful lives of the existing leasehold improvements and furniture placed in service at its premises, which are included as component of property and equipment, net on its unaudited condensed consolidated balance sheets and are fully depreciated as of September 30, 2022 . The Company recorded rent expense of approximately $0.1 million and $0.5 million during the three months and nine months ended September 30, 2022, respectively. There are no future lease payments due under the June 2021 Amended Lease Agreement following termination. Legal Proceedings The Company may from time to time be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings during the three and nine months ended September 30, 2022 and year ended December 31, 2021, and no material legal proceedings are currently pending or, to the best of its knowledge, threatened. Indemnification Obligations The Company agrees to standard indemnification obligations as part of entering into agreements in the ordinary course of business. Pursuant to the indemnification provisions, the Company agrees to indemnify, hold harmless, and to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company’s business partners, in connection with matters specified in the applicable provision, which may include any U.S. patent or any copyright or other intellectual property infringement claim by any third-party with respect to the Company’s products or product liability claims by any third-party with respect to the Company’s products. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. The potential amount of future payments the Company could be required to make under these indemnification obligations is unlimited. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification obligations.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ Equity On August 13, 2019, the Company’s board of directors, and on February 26, 2020, the Company’s stockholders, approved the Company’s restated certificate of incorporation, which became effective upon closing of the IPO on March 16, 2020, to authorize Common stockholders are entitled to receive dividends, as may be declared by the Board, if any, subject to the preferential dividend rights of any preferred stock then outstanding. Through September 30, 2022, no cash dividends have been declared or paid. As of September 30, 2022, 10,000,000 shares of preferred stock were authorized and no shares of preferred stock were issued or outstanding. As of September 30, 2022 and December 31, 2021, the Company has reserved for future issuance the following shares of common stock: September 30, 2022 December 31, 2021 Shares reserved for future issuance under the 2020 Equity Incentive Plan 2,593,338 1,216,532 Shares reserved for future issuance under the 2020 Employee Stock Purchase Plan 438,539 175,667 3,031,877 1,392,199

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Compensation Related Costs [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation 2016 Stock Incentive Plan The Company’s 2016 Stock Incentive Plan, (the “2016 Plan”) provided for the grant of restricted stock, restricted stock units, stock appreciation rights, incentive stock options, non-statutory stock options and other stock-based awards to employees, officers, members of the Board, consultants and advisors of the Company. As of the effective date of the 2020 Equity Incentive Plan (the “2020 Plan”) on March 11, 2020, and as of September 30, 2022, no shares remained available for future issuance under the 2016 Plan. Any options or awards outstanding under the 2016 Plan remain outstanding and effective 2020 Equity Incentive Plan On October 1, 2019, the Company’s board of directors adopted, and on February 26, 2020 the Company’s stockholders approved, the 2020 Plan, which became effective on March 11, 2020. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The number of shares reserved for issuance under the 2020 Plan is the sum of: (1) 1,220,283 shares of the Company’s common stock; plus (2) the number of shares (up to a maximum of 2,091,969 shares) equal to the sum of (x) 228,852 shares, which represents the Company’s common stock reserved for issuance under the 2016 Plan that remained available for grant under the 2016 Plan as of March 11, 2020 and (y) the number of shares of the Company’s common stock subject to outstanding awards granted under the 2016 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right. The number of shares reserved will be annually increased on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2021 and continuing until, and including, the fiscal year ending December 31, 2030, equal to the lesser of (i) 4% of the number of shares of the Company’s common stock outstanding on the first day of such fiscal year and (ii) an amount determined by the Company’s board of directors. On January 1, 2021, 701,930 additional shares were reserved for issuance under the 2020 Plan pursuant to this provision. On January 1, 2022, a further 1,051,490 shares were reserved for future under the 2020 Plan pursuant to this provision. No more than 8,541,982 shares of common stock may be issued as incentive stock options under the 2020 Plan. The shares of common stock underlying any awards that expire, terminate, or are otherwise surrendered, cancelled, forfeited or repurchased by the Company under the 2016 Plan or the 2020 Plan will be added back to the shares of common stock available for issuance under the 2020 Plan As of September 30, 2022, there were 2,593,338 shares available for future issuance under the 2020 Plan. The following table summarizes the Company’s stock option activity: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2021 2,373,024 $ 9.63 8.19 $ — Granted 501,839 1.35 Exercised — — Forfeited (1,040,598 ) 10.16 Outstanding as of September 30, 2022 1,834,265 $ 7.06 7.39 $ 264 Options vested and exercisable as of September 30, 2022 1,155,807 $ 6.93 6.84 $ — The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the period. The weighted-average grant date fair value of the Company’s stock options granted during the nine months ended September 30, 2022 was $1.02. There were no options granted during the three months ended September 30, 2022. The weighted-average grant date fair value of the Company’s stock options granted during each of the three and nine months ended September 30, 2021 was $3.66 and $7.44, respectively. Restricted Stock Units In January 2022, the Company granted 425,289 restricted stock units to employees under the 2020 Plan, which will vest over a four year term. A summary of the restricted stock unit ("RSU") activity and related information is as follows: Number of Shares Weighted- Average Grant Date Fair Value Unvested as of December 31, 2021 — $ — Granted 425,289 1.38 Vested — — Forfeited (211,846) 1.38 Unvested as of September 30, 2022 213,443 $ 1.38 Stock-Based Compensation Stock-based compensation expense included in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Research and development $ (26 ) $ 322 $ 198 $ 1,034 General and administrative 526 681 1,743 1,833 Total stock-based compensation expense $ 500 $ 1,003 $ 1,941 $ 2,867 As of September 30, 2022 and December 31, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $3.0 million and $9.4 million, respectively, which is expected to be recognized over a weighted-average period of 1.94 and 2.65 years, respectively.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company’s otherwise recognizable net deferred tax assets. On March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The Cares Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also established a Paycheck Protection Program whereby certain small businesses are eligible for a loan to fund payroll expenses, rent, and related costs. The CARES Act provided for an Employee Retention Credit (“ERC”), which is a refundable payroll tax credit that encouraged businesses to keep employees on the payroll during the COVID-19 pandemic. Eligible employers are entitled to a refundable tax credit equal to 50% of qualified wages paid to employees between March 13, 2020, and December 31, 2020, up to a maximum of $5,000 credit per employee. In late December 2020 Congress expanded and amended the CARES Act by enacting Public Law 116-260. Per the amendment to the CARES Act, eligible employers are entitled to a refundable tax credit equal to 70% of the qualified wages paid to employees between January 1, 2021, and September 30, 2021, up to a maximum of $10,000 of wages per employee per quarter, with a maximum of $7,000 per employee per calendar quarter. Congress further extended the credit with the American Rescue Plan signed into law on March 11, 2021; the American Rescue Plan extended the credit for the period July 1, 2021 to December 31, 2021 with the same limitations as the prior amendment (i.e., tax credit equal to 70% of qualified wages up to a maximum of $10,000 of wages per employee per quarter). However, on November 15, 2021, President Biden signed into law the Infrastructure Investment and Jobs Act which redacted the credit for calendar quarter 4 of 2021. Qualified Wages must be paid on or after March 13, 2020 and before October 1, 2021, and may include wages paid to employees, as well as so much of the employer’s qualified health plan expenses as are properly allocable to such wages, not to exceed $10,000 per employee for calendar year 2020 or $10,000 per employee per calendar quarter in quarter 1, 2, or 3 of 2021 (“2021 Eligible Quarter”). The Retention Credit may be claimed for up to $5,000 per employee for calendar year 2020 (i.e., 50% of the $10,000 maximum in Qualified Wages for calendar year 2020) or $ 7,000 per employee per 2021 Eligible Quarter (i.e., 70% of the $10,000 maximum in Qualified Wages per 2021 Eligible Quarter). Therefore, the maximum Retention Credit per employee in 2020 is $ 5,000 and in 2021 is $ 21,000 . Based on the Company’s evaluation of this provision and pandemic-related impact on its operations in 2020 and 2021, it was determined that the Company qualified to claim ERC in the second, third and fourth calendar quarters of 2020, as well as in both the first, second, and third calendar quarters of 2021. The Company recognized an ERC of approximately $ 1.0 million as an offset to payroll tax expenses for the year ended December 31, 2021. The Company did no t recognize an ERC for the three and nine months ended September 30, 2022.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	11. Net Loss Per Share Basic and diluted net loss per share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including convertible preferred stock (if any such convertible preferred stock were outstanding), and options to purchase common stock during the period determined using the if-converted method, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same. The Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Options to purchase common stock 2,593,338 2,313,084 2,593,338 2,313,084 Unvested restricted stock units 213,443 — 213,443 — Shares reserved for future issuance under the ESPP 438,539 187,209 438,539 187,209

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions Lundbeck Lundbeckfond Invest A/S is one of the Company’s stockholders and participated in all tranches of the Series A preferred stock financing and both tranches of the Series B preferred stock financing. Prior to the conversion of the Company’s preferred stock, Lundbeckfond Invest A/S owned 5,470,492 shares of Series A Preferred Stock as of December 31, 2019, and 478,749 shares of Series Seed Preferred Stock as of December 31, 2019. Lundbeckfond Invest A/S owned 1,326,111 shares of Series B Preferred Stock as of December 31, 2019. All shares of preferred stock converted into shares of common stock upon closing of the IPO. Lundbeckfond Invest A/S also purchased 187,500 shares of common stock in the IPO. This reflects a 5.1% ownership interest on a fully diluted basis as of September 30, 2022 and December 31, 2021. Mette Kirstine Agger, who was a member of our board of directors until June 29, 2021, is a Managing Partner at Lundbeckfonden Ventures, which is an affiliate of Lundbeckfond Invest A/S. Lundbeck, an affiliate of Lundbeckfond Invest A/S, is also one of the Company’s stockholders and participated in the fourth tranche of the Company’s Series A preferred stock financing. Prior to the conversion of the Company’s preferred stock, Lundbeck owned 499,069 shares of Series A Preferred Stock as of December 31, 2019, as well as 443,271 shares of common stock issued in conjunction with the Lundbeck Agreement (See Note 6). All shares of preferred stock converted into shares of common stock upon closing of the IPO. This reflects a 1.9% ownership interest on a fully diluted basis as of September 30, 2022 and December 31, 2021. Lundbeck did not participate in the Series B Preferred Stock financing. To date, pursuant to the Lundbeck Agreement, the Company has made cash payments to Lundbeck of $1.8 million consisting of an upfront payment and ongoing milestone payments which are recorded as research and development expense. In connection with the Asset Sale, the Lundbeck Agreement will be assigned to Cardurion.

Benefit Plans

Benefit Plans	9 Months Ended
	Sep. 30, 2022
Compensation And Retirement Disclosure [Abstract]
Benefit Plans	13. Benefit Plans The Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code effective as of January 2019. This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the plan may be made at the discretion of the Board. The Company made less than $0.1 million and $0.1 million of contributions for the three and nine months ended September 30, 2022, respectively, and has made $0.3 million of contributions to the plan to date.

Asset Purchase Agreement

Asset Purchase Agreement	9 Months Ended
	Sep. 30, 2022
Asset Purchase Agreement [Abstract]
Asset Purchase Agreement	14. Asset Purchase Agreement On September 6, 2022, the Company entered into an Asset Purchase Agreement with Cardurion, providing for the sale of tovinontrine and all other assets of the Company related to its PDE9 program. Pursuant to the terms of the Asset Purchase Agreement, in addition to $250,000 previously paid by Cardurion to the Company upon execution of a non-binding term sheet, the aggregate purchase price consists of an upfront cash payment of $34,750,000 upon closing of the transaction and a $10,000,000 potential future payment that may become payable if Cardurion achieves a proof of concept milestone or other specified clinical milestones and a $50,000,000 potential future payment that may become payable if Cardurion achieves specified regulatory and/or commercial milestone events, in each case as described in the Asset Purchase Agreement and subject to the terms of the Asset Purchase Agreement. Consummation of the Asset Sale is subject to customary closing conditions, including, without limitation, approval of the sale by the Company’s stockholders.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events Merger Agreement On October 13, 2022, the Company, Merger Sub and Enliven entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Enliven, with Enliven continuing as the Company's wholly owned subsidiary and the surviving corporation of the Merger. If the Merger is completed, the business of Enliven will continue as the business of the combined organization. Consummation of the transactions contemplated by the Merger Agreement is subject to certain closing conditions, including, among other things, (1) approval by our stockholders of the Required Voting Proposal, (2) approval by the Enliven stockholders of the adoption of the Merger Agreement, (3) Nasdaq’s approval of the listing of the shares of our common stock to be issued in connection with the Merger, (4) the effectiveness of the Registration Statement, (5) our net cash as determined in accordance with the Merger Agreement being between $75 million and $95 million, (6) the waiting period under the HSR Act having expired or been terminated and (7) our closing of the previously announced Asset Sale. Each party’s obligation to consummate the Merger is also subject to other specified customary conditions, including the representations and warranties of the other party being true and correct as of the date of the Merger Agreement and as of the closing date of the Merger, generally subject to an overall material adverse effect qualification, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger. Enliven’s obligation to consummate the Merger is also subject to the completion of the Financing Transaction such that Enliven receives gross proceeds of at least $131.6 million and our obligation to consummate the Merger is subject to the completion of the Financing Transaction such that Enliven receives gross proceeds of at least $75.0 million. Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), (a) each then-outstanding share of Enliven common stock (including shares of Enliven common stock issued upon conversion of Enliven preferred stock, which conversion will occur immediately prior to the Effective Time and shares of Enliven common stock issued in the Financing Transaction (as defined below)) will be converted into the right to receive a number of shares of IMARA common stock ( subject to the payment of cash in lieu of fractional shares and after giving effect to the IMARA Reverse Stock Split (as defined below)) calculated in accordance with the Merger Agreement (the ratio of such conversion, the “Exchange Ratio”); and (b) each then-outstanding Enliven stock option to purchase Enliven common stock will be assumed by IMARA, subject to adjustment as set forth in the Merger Agreement. The provisions for calculating the Exchange Ratio are set forth in the Merger Agreement, and assume a valuation for Enliven equal to $324.6 million, plus the proceeds of the Financing Transaction (as defined below), and a valuation for IMARA equal to its net cash as of the business day immediately prior to the closing date of the Merger, plus $10 million, in each case as further described in the Merger Agreement. The Exchange Ratio is also based on the relative capitalizations of the companies. For purposes of calculating the Exchange Ratio, shares of IMARA common stock underlying IMARA stock options outstanding immediately prior to the Effective Time with an exercise price per share of less than or equal to $10.00 (as adjusted for the IMARA Reverse Stock Split) will be deemed to be outstanding, and all shares of Enliven common stock underlying outstanding Enliven stock options, warrants and other derivative securities will be deemed to be outstanding. In connection with the Merger, IMARA will seek the approval of its stockholders to, among other things, (a) issue the shares of IMARA common stock issuable in connection with the Merger under the rules of The Nasdaq Stock Market LLC ("Nasdaq") pursuant to the terms of the Merger Agreement (the "Required IMARA Voting Proposal"), (b) amend its certificate of incorporation to effect a reverse split of IMARA common stock, at a ratio to be determined prior to the Effective Time in accordance with the Merger Agreement (the "Reverse Stock Split"), which is intended to ensure that Nasdaq listing requirements are satisfied and (c) amend certain terms of IMARA’s equity incentive plans as described in the Merger Agreement. Each of IMARA and Enliven has made customary representations, warranties and has agreed to customary covenants in the Merger Agreement. Consummation of the Merger is subject to specified closing conditions. The Merger Agreement contains certain termination rights of each of IMARA and Enliven, including, subject to compliance with the applicable terms of the Merger Agreement, the right of each party to terminate the Merger Agreement to enter into a definitive agreement for a superior proposal. Upon termination of the Merger Agreement under specified circumstances, IMARA may be required to pay Enliven a termination fee of $3.0 million and Enliven may be required to pay IMARA a termination fee of $9.75 million. In certain specified circumstances, Enliven may be required to pay IMARA a termination fee of $3.0 million. Concurrently with the execution and delivery of the Merger Agreement, Enliven entered into a common stock purchase agreement (the "Purchase Agreement") with certain new and existing Enliven investors, pursuant to which Enliven agreed to issue and sell to such investors, and such investors agreed to purchase from Enliven, shares of Enliven common stock for an aggregate purchase price of approximately $164.5 million (the "Financing Transaction"). The closing of the Financing Transaction is conditioned on the satisfaction or waiver of the closing conditions to the Merger as set forth in the Merger Agreement and other customary closing conditions, and is expected to occur immediately prior to the closing of the Merger, in accordance with the terms of the Purchase Agreement. The shares of Enliven common stock to be issued in connection with the Financing Transaction will be converted into the right to receive a number of shares of IMARA common stock in the Merger in accordance with the Exchange Ratio (the "Converted Financing Stock") (subject to the payment of cash in lieu of fractional shares and after giving effect to the Reverse Stock Split). At or prior to the Effective Time, IMARA will enter into a Contingent Value Rights Agreement (the "CVR Agreement") with a rights agent ("Rights Agent") pursuant to which IMARA’s pre­Merger common stockholders will receive one contingent value right ( each, a "CVR") for each outstanding share of IMARA common stock held by such stockholder on such date. Each CVR will represent the contractual right to receive payments upon the occurrence of certain events related to the Asset Sale or a potential sale or license involving IMR-261, in each case as set forth in, and subject to and in accordance with the terms and conditions of, the CVR Agreement. The contingent payments under the CVR Agreement, if they become payable, will become payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that no such proceeds are received, holders of the CVRs will not receive any payment pursuant to the CVR Agreement. There can be no assurance that holders of CVRs will receive any amounts with respect thereto. The right to the contingent payments contemplated by the CVR Agreement is a contractual right only and will not be transferable, except in the limited circumstances specified in the CVR Agreement. The CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in IMARA or any of its affiliates. No interest will accrue on any amounts payable in respect of the CVRs.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021 and notes thereto, included in the Company’s Annual Report on Form 10-K (the “Annual Report”), filed with the SEC on March 15, 2022. The unaudited condensed consolidated interim financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated interim financial statements contain all adjustments which are necessary to present fairly the Company’s financial position as of September 30, 2022, the results of its operations for the three and nine months ended September 30, 2022 and 2021 and cash flows for the nine months ended September 30, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results for the year ending December 31, 2022, or for any future period.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company include the accounts of its wholly owned subsidiaries, IMARA Security Corporation and IMARA E.U. Limited, the latter of which was dissolved in July 2021. All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, accrued research and development expenses, and stock-based compensation expense. Actual results could differ materially from those estimates.
Segments	Segments Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purpose of allocating resources. All of the Company’s long-lived assets are held in the United States.
Comprehensive Loss	Comprehensive Loss Comprehensive loss includes net loss and certain changes in stockholders’ equity that are excluded from net loss. The Company’s comprehensive loss includes unrealized gains and losses (net) on available-for-sale debt securities for the three and nine months ended September 30, 2022 and 2021.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In March 2020, the FASB issued “ASU 2020-03”, Codification Improvements to Financial Instruments (“ASU 2020-03”) which addressed, among other topics, Amendments related to ASU 2016-13 Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13”). The amendments align the contractual term under Topic 326 and Topic 842 (Leases) to be consistent, and also clarifies when an entity should record an allowance for credit losses in accordance with Topic 326. The standard is effective for the Company on January 1, 2023, with early adoption permitted. The Company is currently evaluating the impact of this new guidance on the Company’s consolidated financial statements and related disclosures, but does not expect the adoption of ASU 2020-03 or ASU 2016-13 to be material.

Fair Value of Financial Asset_2

Fair Value of Financial Assets and Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands): September 30, 2022 Quoted Active for Assets Significant Observable Inputs Significant Observable Inputs Description Total (Level 1) (Level 2) (Level 3) Assets: Money market funds, included in cash and cash equivalents $ 46,252 $ 46,252 $ — $ — Marketable securities: Commercial paper 4,397 — 4,397 — Corporate debt securities 2,416 — 2,416 — Total financial assets $ 53,065 $ 46,252 $ 6,813 $ — December 31, 2021 Quoted Active for Assets Significant Observable Inputs Significant Observable Inputs Description Total (Level 1) (Level 2) (Level 3) Assets: Money market funds, included in cash and cash equivalents $ 24,798 $ 24,798 $ — $ — Marketable securities: Commercial paper 26,131 — 26,131 — Corporate debt securities 15,838 — 15,838 — Total financial assets $ 66,767 $ 24,798 $ 41,969 $ —

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2022
Investments Debt And Equity Securities [Abstract]
Summary of Investments	The following table summarizes the Company’s investments (in thousands): September 30, 2022 Amortized Gross Gains Gross Loss Fair Current: Commercial paper $ 4,397 $ — $ — $ 4,397 Corporate debt securities 2,420 — (4 ) 2,416 Total $ 6,817 $ — $ (4 ) $ 6,813 December 31, 2021 Amortized Gross Gains Gross Loss Fair Current: Commercial paper $ 26,131 $ — $ — $ 26,131 Corporate debt securities 15,854 — (16 ) 15,838 Total $ 41,985 $ — $ (16 ) $ 41,969

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2022
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following (in thousands): September 30, 2022 December 31, 2021 Accrued research and development expenses $ 136 $ 2,288 Accrued compensation and benefits 164 2,024 Accrued professional services 733 249 Accrued other 18 43 Total accrued expenses $ 1,051 $ 4,604

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Shares Reserved for Future Issuance	As of September 30, 2022 and December 31, 2021, the Company has reserved for future issuance the following shares of common stock: September 30, 2022 December 31, 2021 Shares reserved for future issuance under the 2020 Equity Incentive Plan 2,593,338 1,216,532 Shares reserved for future issuance under the 2020 Employee Stock Purchase Plan 438,539 175,667 3,031,877 1,392,199

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Compensation Related Costs [Abstract]
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2021 2,373,024 $ 9.63 8.19 $ — Granted 501,839 1.35 Exercised — — Forfeited (1,040,598 ) 10.16 Outstanding as of September 30, 2022 1,834,265 $ 7.06 7.39 $ 264 Options vested and exercisable as of September 30, 2022 1,155,807 $ 6.93 6.84 $ —
Summary of Restricted Stock Units Activity	A summary of the restricted stock unit ("RSU") activity and related information is as follows: Number of Shares Weighted- Average Grant Date Fair Value Unvested as of December 31, 2021 — $ — Granted 425,289 1.38 Vested — — Forfeited (211,846) 1.38 Unvested as of September 30, 2022 213,443 $ 1.38
Summary of Stock-Based Compensation Expense	Stock-based compensation expense included in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Research and development $ (26 ) $ 322 $ 198 $ 1,034 General and administrative 526 681 1,743 1,833 Total stock-based compensation expense $ 500 $ 1,003 $ 1,941 $ 2,867

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Anti Dilutive Potential Common Shares Excluded From Computation of Diluted Net Loss Per Share	The Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Options to purchase common stock 2,593,338 2,313,084 2,593,338 2,313,084 Unvested restricted stock units 213,443 — 213,443 — Shares reserved for future issuance under the ESPP 438,539 187,209 438,539 187,209

Nature of the Business - Additi

Nature of the Business - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands				9 Months Ended
	Apr. 12, 2022	Jul. 16, 2021	Apr. 01, 2021	Sep. 30, 2022	Dec. 31, 2021
Nature Of Business [Line Items]
Workforce reduction, cost	$ 2,100
Cash, cash equivalents, and investments				$ 56,300
Accumulated deficit				$ 178,194	$ 147,497
Common stock issued and sold		8,333,333
Common stock, shares issued				26,287,264	26,287,264
Net proceeds from issuance of common stock		$ 46,800
Public offering price per share		$ 6
Maximum
Nature Of Business [Line Items]
Common stock issued and sold			200,000,000
Aggregate gross proceeds of common stock issued and sold			$ 75,000
At The Market Offering
Nature Of Business [Line Items]
Common stock, shares issued				231,291
Net proceeds from issuance of common stock				$ 1,400

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details)	9 Months Ended
	Sep. 30, 2022 Segment
Accounting Policies [Abstract]
Number of operating segments	1

Fair Value of Financial Asset_3

Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Assets:
Marketable securities	$ 6,813	$ 41,969
Fair Value Measurements Recurring
Assets:
Total	53,065	66,767
Fair Value Measurements Recurring | Money Market Funds
Assets:
Cash and cash equivalents	46,252	24,798
Fair Value Measurements Recurring | Commercial Paper
Assets:
Marketable securities	4,397	26,131
Fair Value Measurements Recurring | Corporate Debt Securities
Assets:
Marketable securities	2,416	15,838
Fair Value Measurements Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total	46,252	24,798
Fair Value Measurements Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds
Assets:
Cash and cash equivalents	46,252	24,798
Fair Value Measurements Recurring | Significant Other Observable Inputs (Level 2)
Assets:
Total	6,813	41,969
Fair Value Measurements Recurring | Significant Other Observable Inputs (Level 2) | Commercial Paper
Assets:
Marketable securities	4,397	26,131
Fair Value Measurements Recurring | Significant Other Observable Inputs (Level 2) | Corporate Debt Securities
Assets:
Marketable securities	$ 2,416	$ 15,838

Investments - Summary of Invest

Investments - Summary of Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 6,817	$ 41,985
Gross Unrealized Loss	(4)	(16)
Fair Value	6,813	41,969
Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	4,397	26,131
Fair Value	4,397	26,131
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	2,420	15,854
Gross Unrealized Loss	(4)	(16)
Fair Value	$ 2,416	$ 15,838

Investments - Additional Inform

Investments - Additional Information (Details) $ in Millions	Sep. 30, 2022 USD ($) Position	Dec. 31, 2021 USD ($) Position
Investments Debt And Equity Securities [Abstract]
Number of available-for-sale securities in unrealized loss positions for less than twelve months | Position	1	7
Available-for-sale securities in unrealized loss positions for less than twelve months | $	$ 2.4	$ 15.8

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Accrued research and development expenses	$ 136	$ 2,288
Accrued compensation and benefits	164	2,024
Accrued professional services	733	249
Accrued other	18	43
Total accrued expenses	$ 1,051	$ 4,604

Accrued Expenses - Additional I

Accrued Expenses - Additional Information (Details) $ in Millions	Apr. 12, 2022 USD ($) Employee
Payables And Accruals [Line Items]
Workforce reduction, cost | $	$ 2.1
Workforce Reduction
Payables And Accruals [Line Items]
Percentage of workforce reduction	83%
Number of remaining full-time employees not eliminated | Employee	6

License Agreements - Additional

License Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended	78 Months Ended
	Apr. 30, 2016	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2022	Jul. 16, 2021	Dec. 31, 2019	Nov. 30, 2018
License Agreements [Line Items]
Common stock, shares issued		26,287,264	26,287,264	26,287,264	26,287,264
Public offering price per share						$ 6
Lundbeck Agreement | Lundbeck
License Agreements [Line Items]
Maximum development milestones payments due	$ 23,500,000
Maximum development milestones payments due for other than licensed product	$ 11,800,000
Upfront and ongoing milestone payments		$ 0	$ 0	$ 0
Common stock, shares issued	167,523						443,271
Outstanding equity percentage pursuant to restricted stock agreement	8%
Notice period for agreement termination			180 days
Lundbeck Agreement | Lundbeck | Series A Preferred Stock | Fourth Tranche
License Agreements [Line Items]
Public offering price per share								$ 1
Lundbeck Agreement | Lundbeck | Research and Development Expense
License Agreements [Line Items]
Upfront and ongoing milestone payments					$ 1,800,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	1 Months Ended			3 Months Ended	9 Months Ended
	Jul. 31, 2022	Jun. 30, 2021	May 31, 2019	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Commitments and Contingencies [Line Items]
Operating lease description					In June 2021, the Company entered into an amendment to the May 2019 Lease Agreement (the “June 2021 Amended Lease Agreement”). Under the terms of the June 2021 Amended Lease Agreement, the Company expanded its current premises in Boston, Massachusetts by an additional 5,026 square feet, bringing the total office space to 9,236 square feet.
Rent expense				$ 100,000	$ 500,000
Depreciation expense					$ 612,000	$ 74,000
Termination Agreement
Commitments and Contingencies [Line Items]
Lease termination fee	$ 300,000
Forfeiture of security deposit	200,000
Additional lease termination fee	100,000
Termination Agreement | Maximum
Commitments and Contingencies [Line Items]
Gain on remeasurement of right of use assets and operating lease liabilities	$ 100,000
May 2019 Lease Agreement
Commitments and Contingencies [Line Items]
Operating lease description					In May 2019, the Company entered into an operating lease agreement (the “May 2019 Lease Agreement”) for office space totaling 4,210 square feet, located in Boston, Massachusetts with a 62-month term.
Operating lease term of contract			62 months
Operating lease, payments			$ 300,000
Security deposit			$ 100,000
Additional security deposit		$ 100,000
June 2021 Amended Lease Agreement
Commitments and Contingencies [Line Items]
Security deposit		$ 200,000
Lease expiration date		Mar. 31, 2027
Operating lease, payments		$ 3,100,000		$ 0	$ 0
Rent expense		$ 600,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Mar. 16, 2020	Dec. 31, 2019
Equity [Abstract]
Preferred stock, authorized	10,000,000	0	10,000,000
Preferred stock par value per share	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000	200,000,000	100,000,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Cash dividends	$ 0
Preferred stock, shares authorized	10,000,000	0	10,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Shares Reserved for Future Issuance (Details) - shares	Sep. 30, 2022	Jan. 01, 2022	Dec. 31, 2021	Jan. 01, 2021
Class Of Stock [Line Items]
Shares reserved for future issuance	3,031,877		1,392,199
2020 Equity Incentive Plan
Class Of Stock [Line Items]
Shares reserved for future issuance	2,593,338	1,051,490	1,216,532	701,930
2020 Employee Stock Purchase Plan
Class Of Stock [Line Items]
Shares reserved for future issuance	438,539		175,667

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 11, 2020	Jan. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jan. 01, 2022	Jan. 01, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares remaining available for future issuance			3,031,877		3,031,877		1,392,199
Share-based compensation award, granted					501,839
Share-based compensation award, weighted-average fair value			$ 0	$ 3.66	$ 1.02	$ 7.44
Unrecognized stock-based compensation expense			$ 3		$ 3		$ 9.4
Expected weighted average period to recognize expense					1 year 11 months 8 days		2 years 7 months 24 days
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted		425,289			425,289
Vesting term		4 years
2016 Stock Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares remaining available for future issuance	228,852		0		0
2020 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares remaining available for future issuance			2,593,338		2,593,338		1,216,532	1,051,490	701,930
Number of shares of common stock that may be issued accordance with plan	1,220,283
Description of changes in the number of shares reserved for issuance					The number of shares reserved will be annually increased on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2021 and continuing until, and including, the fiscal year ending December 31, 2030, equal to the lesser of (i) 4% of the number of shares of the Company’s common stock outstanding on the first day of such fiscal year and (ii) an amount determined by the Company’s board of directors.
Common stock outstanding percent	4%
2020 Equity Incentive Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares of common stock that may be issued accordance with plan	8,541,982
Number of shares authorized	2,091,969

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Compensation Related Costs [Abstract]
Number of Shares, Beginning Balance	2,373,024
Number of Shares, Granted	501,839
Number of Shares, Forfeited	(1,040,598)
Number of Shares, Ending Balance	1,834,265	2,373,024
Number of Shares, Options vested and exercisable	1,155,807
Weighted-Average Exercise Price, Beginning Balance	$ 9.63
Weighted-Average Exercise Price, Granted	1.35
Weighted-Average Exercise Price, Forfeited	10.16
Weighted-Average Exercise Price, Ending Balance	7.06	$ 9.63
Weighted-Average Exercise Price, Options vested and exercisable	$ 6.93
Weighted-Average Remaining Contractual Term, Outstanding	7 years 4 months 20 days	8 years 2 months 8 days
Weighted-Average Remaining Contractual Term, Options vested and exercisable	6 years 10 months 2 days
Aggregate Intrinsic Value, Balance	$ 264

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	1 Months Ended	9 Months Ended
	Jan. 31, 2022	Sep. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	425,289	425,289
Number of Shares, Forfeited		(211,846)
Number of Shares, Unvested, Ending Balance		213,443
Weighted-Average Grant Date Fair Value, Granted		$ 1.38
Weighted-Average Grant Date Fair Value, Forfeited		1.38
Weighted-Average Grant Date Fair Value, Unvested, Ending Balance		$ 1.38

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 500	$ 1,003	$ 1,941	$ 2,867
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	(26)	322	198	1,034
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 526	$ 681	$ 1,743	$ 1,833

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	3 Months Ended				9 Months Ended		10 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021	Dec. 31, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Income Tax Disclosure [Abstract]
Maximum refundable tax credit allowed per employee							$ 5,000
Percentage of qualified wages		70	70	70		70	50		50
Maximum qualified wages entitled per employee		$ 10,000	$ 10,000	$ 10,000					$ 10,000
Maximum employee retention credit available per employee		$ 7,000	$ 7,000	$ 7,000				$ 21,000	$ 5,000
Qualified wages, description					In late December 2020 Congress expanded and amended the CARES Act by enacting Public Law 116-260. Per the amendment to the CARES Act, eligible employers are entitled to a refundable tax credit equal to 70% of the qualified wages paid to employees between January 1, 2021, and September 30, 2021, up to a maximum of $10,000 of wages per employee per quarter, with a maximum of $7,000 per employee per calendar quarter. Congress further extended the credit with the American Rescue Plan signed into law on March 11, 2021; the American Rescue Plan extended the credit for the period July 1, 2021 to December 31, 2021 with the same limitations as the prior amendment (i.e., tax credit equal to 70% of qualified wages up to a maximum of $10,000 of wages per employee per quarter). However, on November 15, 2021, President Biden signed into law the Infrastructure Investment and Jobs Act which redacted the credit for calendar quarter 4 of 2021. Qualified Wages must be paid on or after March 13, 2020 and before October 1, 2021, and may include wages paid to employees, as well as so much of the employer’s qualified health plan expenses as are properly allocable to such wages, not to exceed $10,000 per employee for calendar year 2020 or $10,000 per employee per calendar quarter in quarter 1, 2, or 3 of 2021 (“2021 Eligible Quarter”).
Employee retention credit as offset to payroll tax expense	$ 0				$ 0			$ 1,000,000

Net Loss Per Share - Anti Dilut

Net Loss Per Share - Anti Dilutive Potential Common Shares Excluded From Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Unvested Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per common share	213,443		213,443
Shares reserved for future issuance under the ESPP
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per common share	438,539	187,209	438,539	187,209
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per common share	2,593,338	2,313,084	2,593,338	2,313,084

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($)			3 Months Ended	9 Months Ended	12 Months Ended	78 Months Ended
	Jul. 16, 2021	Mar. 16, 2020	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2022	Dec. 31, 2019	Apr. 30, 2016
Related Party Transaction [Line Items]
Number of common stock purchased	8,333,333
Common stock, shares issued			26,287,264	26,287,264	26,287,264	26,287,264
Lundbeckfond Invest A/S
Related Party Transaction [Line Items]
Ownership interest percentage			5.10%	5.10%	5.10%	5.10%
Lundbeckfond Invest A/S | Initial Public Offering | Common Stock
Related Party Transaction [Line Items]
Number of common stock purchased		187,500
Lundbeck | Lundbeck Agreement
Related Party Transaction [Line Items]
Ownership interest percentage			1.90%	1.90%	1.90%	1.90%
Common stock, shares issued							443,271	167,523
Upfront and ongoing milestone payments			$ 0	$ 0	$ 0
Lundbeck | Lundbeck Agreement | Research and Development Expense
Related Party Transaction [Line Items]
Upfront and ongoing milestone payments						$ 1,800,000
Series A Preferred Stock | Lundbeckfond Invest A/S
Related Party Transaction [Line Items]
Shares owned							5,470,492
Series A Preferred Stock | Lundbeck | Lundbeck Agreement
Related Party Transaction [Line Items]
Shares owned							499,069
Series Seed Preferred Stock | Lundbeckfond Invest A/S
Related Party Transaction [Line Items]
Shares owned							478,749
Series B Preferred Stock | Lundbeckfond Invest A/S
Related Party Transaction [Line Items]
Shares owned							1,326,111

Benefit Plans - Additional Info

Benefit Plans - Additional Information (Details) - Defined Contribution Savings Plan - USD ($) $ in Millions	3 Months Ended	9 Months Ended	78 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2022
Defined Contribution Plan Disclosure [Line Items]
Contribution to defined contribution savings plan		$ 0.1	$ 0.3
Maximum
Defined Contribution Plan Disclosure [Line Items]
Contribution to defined contribution savings plan	$ 0.1

Asset Purchase Agreement - Addi

Asset Purchase Agreement - Additional Information (Details) $ in Thousands	Oct. 06, 2022 USD ($)
Asset Purchase Agreement [Line Items]
Amount received upon execution of non-binding term sheet	$ 250,000
Upfront cash payment	34,750,000
Proof of Concept Milestone or Other Specified Clinical Milestones
Asset Purchase Agreement [Line Items]
Potential future payments	10,000,000
Specified Regulatory or Commercial Milestone Events
Asset Purchase Agreement [Line Items]
Potential future payments	$ 50,000,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Subsequent Event	Oct. 13, 2022 USD ($) $ / shares
Merger Agreement
Subsequent Event [Line Items]
Termination fee	$ 3,000,000
Maximum | Merger Agreement
Subsequent Event [Line Items]
Financing transaction receives gross proceeds	75,000,000
Enliven | Merger Agreement
Subsequent Event [Line Items]
Assume valuation of Enliven	324,600,000
Cash	10,000,000
Termination fee	9,750,000
Additional termination fee	3,000,000
Financing transaction, aggregate purchase price of common stock	164,500,000
Interest amounts payable under CVR agreement	0
Enliven | Minimum [Member]
Subsequent Event [Line Items]
Net cash	75,000,000
Enliven | Maximum
Subsequent Event [Line Items]
Net cash	$ 95,000,000
Enliven | Maximum | Merger Agreement
Subsequent Event [Line Items]
Exercise price per share | $ / shares	$ 10
Financing transaction receives gross proceeds	$ 131,600,000